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Available online 17 June 2016Lipid nanocarriers are considered as promising candidates for drug delivery and cancer targeting because of their
low toxicity, biodegradability and capacity to encapsulate drugs and/or contrasting agents. However, their bio-
medical applications are currently limited because of a poor understanding of their integrity in vivo. To address
this problem, we report on ﬂuorescent nano-emulsion droplets of 100 nm size encapsulating lipophilic near-in-
frared cyanine 5.5 and 7.5 dyeswith a help of bulky hydrophobic counterion tetraphenylborate. Excellent bright-
ness and efﬁcient Förster Resonance Energy Transfer (FRET) inside lipid NCs enabled for the ﬁrst time
quantitative ﬂuorescence ratiometric imaging of NCs integrity directly in the blood circulation, liver and tumor
xenografts of livingmice using awhole-animal imaging set-up. This uniquemethodology revealed that the integ-
rity of our FRET NCs in the blood circulation of healthy mice is preserved at 93% at 6 h of post-administration,
while it drops to 66% in the liver (half-life is 8.2 h). Moreover, these NCs show fast and efﬁcient accumulation
in tumors, where they enter in nearly intact form (77% integrity at 2 h) before losing their integrity to 40% at
6 h (half-life is 4.4 h). Thus, we propose a simple and robust methodology based on ratiometric FRET imaging
in vivo to evaluate quantitatively nanocarrier integrity in small animals.Wealso demonstrate that nano-emulsion
droplets are remarkably stable nano-objects that remain nearly intact in the blood circulation and release their
content mainly after entering tumors.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
Lipid nanocarriers
In vivo imaging
Near-infrared FRET
Nanocarrier integrity
Enhanced permeability and retention
Tumor1. Introduction
Nanoscale vehicles (nanocarriers, NCs) become indispensable tools
for in vivo imaging [1–3], drug delivery [4,5] and image-guided surgery
[6,7]. One key requirement that any NC has tomeet is tomaintain its in-
tegrity until it reaches the target, for example a tumor [8,9]. This would
ensure robust delivery of active molecules and/or provide the best sig-
nal to noise ratio when NCs are used as contrasting agents. However,
suitable methods for assessing nanocarrier stability and the cargo leak-
age (such as dialysis, size exclusion chromatography, FCS, etc) are
sparse and mostly operate in vitro [10]. Therefore, while providing.goetz@inserm.fr (J.G. Goetz),
B.V. This is an open access article uuseful information, thesemodel experiments cannot resolve fundamen-
tal issues such as the passage of NCs through the bloodstream,which in-
cludes shear forces, opsonization and uptake, and other undesirable
interactions with off-target cells [11–13]. Moreover, in the context of
tumor targeting, it is of utmost importance to assess whether NCs are
capable of maintaining their load upon extravasation from the systemic
circulation into the tumor (Fig. 1). Additionally, a reliable method for
assessing their integrity can inform on the time scale of release of NCs'
content upon tumor targeting through EPR (enhanced permeation
and retention) effect [14,15]. Therefore, it is essential to monitor the in-
tegrity of the nanocarriers in vivo, preferably in real time. Current
methods to study the integrity of the nanocarriers in vivo are very lim-
ited. In addition to radiolabelling assays [16], the highly promising ap-
proach is ﬂuorescence imaging in the near-infrared (NIR) region,
whichnow ranges from classical 2D imaging of small animals up toﬂuo-
rescence-mediated tomography that enables quantitative 3D imagingnder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Concept of FRET NCs that can report on their integrity by change in their emission color. Chemical structures of oil Labrafac WL (medium chain triglyceride) and Cremophor ELP
(PEGylated surfactant) as well as lipophilic cyanine 5.5 and 7.5 dyes (Cy5.5LP and Cy7.5LP) with their bulky hydrophobic counterions are shown.
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ster Resonance Energy Transfer (FRET), which acts as a molecular
ruler between the donor and acceptor dyes and has been extensively
used to characterize properties of bio-/nano-materials and their re-
sponse to biological environments [13,21–23]. It is particularly suitable
to study the integrity of a nanocarrier, because of exquisite sensitivity of
FRET to changes in the donor acceptor distance. Thus, encapsulation of
both donor and acceptor inside a nanocarrier should ensure high FRET
efﬁciency, while the loss of the nanocarrier integrity associated with
the release of its components into the medium should result in the
loss of the FRET signal. Moreover, when FRET occurs between two ﬂuo-
rescent dyes, dual emission of NCs can be obtained, which opens possi-
bilities for quantitative ratiometric measurements using ﬂuorescence
detection in two distinct optical windows. It is only very recently that
FRET imaging has been used for monitoring in vivo the integrity of
NCs. It has been successfully applied to monitor biodistribution and in-
tegrity of polymermicelles [24], hybrid organic-inorganic nanoparticles
[9] and nanoemulsion droplets [25]. However, these studies only
showed global FRET signal from the mice or a tumor, without imaging
directly the particle integrity in the blood circulation, where these
nanocarriers are actually injected. For this purpose, only indirect ex
vivomeasurements and intravital microscopy, which requires complex
dedicated setup, were realized to date [9,26,27]. Moreover, the studies
were limited to qualitative evaluation and no quantiﬁcation of
nanocarrier integrity directly in livingmicewas reported to date. Quan-
titative in vivo ﬂuorescence imaging of NCs integrity can be achieved
only after some key limitations of existing ﬂuorescent NCs are ad-
dressed. The ﬁrst limitation is the insufﬁcient ﬂuorescence signal from
NCs that is contaminated by the background from animal tissue. This
could be overcome by high dye loading into NCs with minimal self-
quenching of the encapsulated dyes and injecting large quantities of
NCs into mice without toxic effects. Moreover, the loaded dyes should
operate in the NIR region (N700 nm), where the absorption, light-scat-
tering and auto-ﬂuorescence of the tissue are minimal [28–30]. Second,
intensity of the FRET signal was usually analyzed, making the assess-
ment of nanocarrier integrity only qualitative. Quantiﬁcation requires
internal control, which can be realized by ratiometric FRET imaging, ob-
tained by division of two images (e.g. acceptor/donor). In contrast to in-
tensity, the measured ratio values are absolute, being independent of
concentration of emissive species and light source intensity [31,32].However, only one rare example used ratio imaging in application to an-
alyze FRET of nanocarriers in vivo [33]. The problem is that inmajority of
examples FRET donor emits below near-infrared (NIR) window
(b700 nm), so that its signal is strongly attenuated by tissue absorption
and contaminated by light scattering and auto-ﬂuorescence. Therefore,
quantitative and reliable ratiometric in vivo imaging requires both
donor and acceptor species to emit in the near-infrared (NIR) region
above 700 nm.
Among the existing nanocarriers for drugs and contrasting agents in
the biomedical research, lipid nano-emulsion emerged recently as a
promising alternative [34–36]. Although nano-emulsions were mainly
used for the last N20 years as template for nanoparticle preparation
[37], only in the last years they attracted attention as nano-carriers in
pharmacy and cosmetics application [38,39]. Nano-emulsiﬁcations en-
able preparation of lipid nanocarriers of well-deﬁned size from FDA ap-
proved materials using direct approaches that do not use organic
solvents [40]. This feature is particularly attractive for high quality ﬂuo-
rescence imaging as it enables injecting maximal amount of
nanocarriers with minimal harm to an animal [34,35]. However, as
nano-emulsions are essentially liquid objects, two major problems
need to be addressed before they can be broadly used in drug delivery
and/or as contrasting agents. First, efﬁcient encapsulation of material
and active compounds, without fast leakage, needs to be achieved. Sec-
ond, in vivo stability is required to ensure proper delivery. Both issues
are actively debated over the last years [25,41–43]. Recently, we intro-
duced an original concept to improve the loading of cyanine dyes into
the oil droplet, which is based on the use of hydrophobic counterions
[44]. Cyanine dyes usually bear inorganic counterions such as perchlo-
rate or iodide that are responsible for poor solubility of these dyes in
oils. By replacing these ions with tetraphenyl borate (TPB), we were
able to improve solubility N40-fold and create 90 nm lipid droplets
bearing exceptional number of cyanine dyes (~12,000 per droplet,
8 wt% dye loading) that remained efﬁciently ﬂuorescent [44]. The ex-
treme brightness of these NCs enabled pioneer single particle tracking
in vivo in a zebraﬁsh embryo model. However, this unique counterion
approach has never been applied to NIR cyanine dyes, required for in
vivo imaging, and it has never been used to generate FRET inside
nanocarriers, needed to assess the NCs integrity.
In the present work, we synthesized lipophilic cyanine 5.5 and 7.5
dyes bearing long alkyl chains and TPB counterion (Cy5.5LP and
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nanocarriers at concentrations required for highly efﬁcient FRET, i.e.
1% in oil. These dyes ideally ﬁt the NIR spectral region for in vivo imag-
ing, where, notably, our cyanine 7.5 is an apolar analogue of indocya-
nine green commonly used for in vivo imaging [45,46]. The obtained
ultrabright FRET NCs were successfully injected and monitored in
healthy and tumor-bearing mice. We were able, for the ﬁrst time, to vi-
sualize and quantitatively assess lipid nanocarrier integrity directly in
the bloodstream, liver and tumor of living mice. We showed that lipid
NCs remain nearly intact in the blood circulation, and they can enter
the tumor with minimal loss of their integrity followed by the release
their content with a half-life of 4.4 ± 0.3 h. Thus, we provide a robust
imagingmethodology to follow the evolution of lipid NCs in vivo, show-
ing their remarkable stability in vivo and capacity to deliver their con-
tent into the target cancer tissues.
2. Materials and methods
2.1. Materials
All chemicals and solvents for synthesis were from Sigma Aldrich.
Cremophor ELP® (Kolliphor ELP®) was provided by BASF
(Ludwigshafen, Germany), LabrafacWL® (medium chain triglycerides)
byGattefossé (Saint-Priest, France). Ultrapurewaterwas obtained using
a MilliQ® ﬁltration system (Millipore, Saint-Quentin-en-Yvelines,
France). Fetal bovine serum (FBS) was acquired from Lonza (Verviers,
Belgium) and Gibco-Invitrogen (Grand Island, USA).
2.2. Synthesis of Cy5.5LP and Cy7.5LP
2.2.1. 1,1,2-trimethyl-3-octadecyl-1H-benzo[e]indol-3-ium iodide (1)
250mL round-bottomﬂask equippedwithmagnetic stirring barwas
charged with 1,1,2-trimethylbenz[e]indole (1 eq., 6.88 g, 32.9 mmol)
and 1-iodooctadecane (2 eq., 25 g, 65.7 mmol), 100 mL of 2-butanone
was added subsequently. Reaction mixture was reﬂuxed for 24 h, then
cooled down to r.t. Reaction mixture was cooled down to r.t., diethyl
ether was added and formed solid part was ﬁltered off and washed
with 100 mL of diethyl ether. Obtained crystals of crude product were
redissolved in DCM and precipitated back while by adding diethyl
ether, afterwards ﬁltered and washed with diethyl ether. Product was
obtained as slightly green crystals in 76% yield (14.73 g).
1H NMR (400 MHz, CDCl3) δ 8.10 (d, J = 8.7 Hz, 1H), 8.08 (dd, J =
8.0, 1.1 Hz, 1H), 8.04 (dd, J= 8.2, 1.3 Hz, 1H), 7.76 (d, J= 8.9 Hz, 1H),
7.72 (ddd, J= 8.3, 6.9, 1.4 Hz, 1H), 7.65 (ddd, J= 8.1, 6.9, 1.2 Hz, 1H),
4.78 (t, J = 7.7 Hz, 2H), 3.19 (s, 3H), 1.97 (p, J = 7.8 Hz, 2H), 1.87 (s,
6H), 1.52–1.41 (m, 2H), 1.40–1.30 (m, 2H), 1.28–1.19 (m, 26H), 0.85
(t, J= 7.0 Hz, 3H).
13C NMR (100MHz, CDCl3) δ 195.25, 138.34, 137.29, 133.82, 131.56,
130.17, 128.77, 127.97, 127.74, 122.96, 112.59, 56.04, 50.56, 32.00,
29.77, 29.76, 29.73, 29.70, 29.65, 29.55, 29.43, 29.41, 29.24, 28.26,
26.92, 22.85, 22.76, 17.03, 14.18.
HRMS (m/z): [M]+ calcd for C33H52N 462.40943; found 462.40854.
2.2.2. Dioctadecylcyanine 5.5 chloride (2)
1,1,2-trimethyl-3-octadecyl-1H-benzo[e]indol-3-ium iodide (1)
(1 eq., 2 g, 3.39 mmol) was placed in 50 mL round-bottom ﬂask.
10 mL of dry pyridine was added via syringe. Then, 1,1,3,3-
tetramethoxypropane (1.5 eq., 0.835 g, 0.838 mL, 5.09 mmol) was
quickly added dropwise to the boiling solution of indoleninium salt
using syringe. Reaction mixture was stirred under reﬂux for 3 h. After
cooling down to room temperature solvent was removed under re-
duced pressure. To the obtained residue 50 mL of dichloromethane
were added. Obtained solution was washed three times with 1 N HCl,
then with brine and water. The crude product was puriﬁed by ﬂash col-
umn chromatography on silica gel using ethyl acetate/dichloromethane(9:1) mixture as eluent. Cyanine was obtained as dark blue-greenish
viscous oil in 76% yield (2.8 g).
1H NMR (400 MHz, CDCl3) δ 8.55 (t, J = 13.0 Hz, 2H), 8.20 (d, J =
8.5 Hz, 2H), 7.90 (d, J = 8.6 Hz, 4H), 7.64–7.54 (m, 2H), 7.44 (t, J =
7.5 Hz, 2H), 7.32 (d, J= 8.8 Hz, 2H), 6.74 (t, J = 12.4 Hz, 1H), 6.24 (d,
J = 13.7 Hz, 2H), 4.14 (t, J = 7.5 Hz, 4H), 2.12 (s, 12H), 1.83 (p, J =
7.6 Hz, 4H), 1.46 (p, J= 7.6, 7.0 Hz, 4H), 1.40–1.33 (m, 4H), 1.30–1.18
(m, 52H), 0.85 (t, J= 6.7 Hz, 6H).
13C NMR (100MHz, CDCl3) δ 174.60, 153.33, 139.40, 134.46, 131.81,
130.44, 129.94, 128.32, 127.83, 125.11, 122.65, 110.44, 103.10, 51.53,
44.64, 32.00, 29.79, 29.77, 29.74, 29.70, 29.66, 29.55, 29.48, 29.44,
27.93, 27.80, 27.08, 22.77, 14.21.
HRMS (m/z): [M]+ calcd for C69H103N2 959.81158; found 959.8098.
2.2.3. Dioctadecylcyanine 7.5 chloride (3)
1,1,2-trimethyl-3-octadecyl-1H-benzo[e]indol-3-ium iodide (1)
(2.2 eq., 1029 mg, 1.75 mmol) and glutaconaldehydedianil hydrochlo-
ride (1 eq., 226mg, 0.794mmol)weremixed in 10mLof pyridine, after-
wards Ac2O (13.4 eq., 1087 mg, 1 mL, 10.6 mmol) was added and the
reaction mixture was heated to 60 °C while stirring and left for 3 h.
After reaction was ﬁnished, solvents were evaporated at vacuum, and
the crude product was dissolved in DCM, washed with 0.1 N HCl (3
times), brine and water. DCM layer was dried over Na2SO4, the solvent
was evaporated and the product was puriﬁed by column chromatogra-
phy on silica (gradient DCM/MeOH 99/1–95/5). Product was obtained
as a green solid (926 mg, 0.906 mmol, 52%).
1H NMR (400 MHz, CDCl3): δ 8.16 (d, J = 8 Hz, 2H), 8.06 (t, J =
12 Hz, 2H), 7.97 (bs, 1H), 7.92 (d, J= 8 Hz, 4H), 7.61 (t, J= 7 Hz, 2H),
7.46 (t, J = 7 Hz, 2H), 7.35 (d, J = 9 Hz, 2H), 6.67 (t, J = 12 Hz, 2H),
6.25 (d, J= 12 Hz, 2H), 4.14 (bs, 4H), 2.04 (s, 12H), 1.87 (m, J= 7 Hz,
4H), 1.49 (m, J = 7 Hz, 4H), 1.39 (m, J = 7 Hz, 4H), 1.26 (bs, 52H),
0.88 (t, J= 7 Hz, 6H).
13CNMR (100MHz, CDCl3): δ 173.07, 157.04, 151.02, 139.74, 133.98,
131.83, 130.59, 130.09, 128.41, 127.87, 126.27, 125.06, 122.47, 110.56,
103.39, 51.155, 44.76, 32.06, 29.842, 29.807, 29.76, 29.72, 29.60, 29.53,
29.50, 27.86, 27.14, 22.82, 14.26.
HRMS (m/z): [M]+ calcd. For C71H105N2+ 985.8272; found 985.8290.
2.2.4. Dioctadecylcyanine 5.5 tetraphenylborate (Cy5.5LP)
Dioctadecylcyanine 5.5 chloride (1 eq., 100 mg, 0.1 mmol) was dis-
solved in 5 mL of DCM, sodium tetraphenylborate (3 eq., 103 mg,
0.301 mmol) was added and the dispersion was sonicated for 5 min.
TLC control has shown full conversion. Afterwards, themixture was pu-
riﬁed on a silica column, eluent DCM/MeOH 95/5 (product goes almost
with front). Dioctadecylcyanine 5.5 tetraphenylborate (109.2 mg,
0.085 mmol, 85%) was obtained as blue-green viscous oil and used
without further characterisation.
2.2.5. Dioctadecylcyanine 7.5 tetraphenylborate (Cy7.5LP)
Dioctadecylcyanine 7.5 chloride (1 eq., 200mg, 0.18mmol) was dis-
solved in 5 mL of DCM, sodium tetraphenylborate (3 eq., 184 mg,
0.539 mmol) was added and the dispersion was sonicated for 5 min.
TLC control has shown full conversion. Afterwards, themixture was pu-
riﬁed on a silica column, eluent DCM/MeOH 95/5 (product goes almost
with front). Dioctadecylcyanine 7.5 tetraphenylborate (218 mg,
0.167 mmol, 93%) was obtained as green viscous oil and used without
further characterisation.
2.3. Formulation and characterisation of lipid nanocarriers
Dye loaded nanoemulsions were produced by spontaneous nano-
emulsiﬁcation. Brieﬂy, the dyes (Cy5.5LP and Cy7.5LP) were ﬁrstly dis-
solved in Labrafac WL® (56 mg) at concentrations ranging from 0.1 to
1% by weight. Then, Cremophor ELP® (also called Kolliphor ELP®)
was added (44mg), and themixturewas homogenized undermagnetic
stirring at 37 °C for 10 min up to complete homogenisation. Finally,
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water (230 mg). Size distributions were determined by dynamic light
scattering using a Zetasizer Nano series DTS 1060 (Malvern Instruments
S.A).
2.4. Fluorescence spectroscopy
Absorption and ﬂuorescence spectra were recorded on a Cary 4
spectrophotometer (Varian) and a Fluoromax 4 (Jobin Yvon, Horiba)
spectroﬂuorometer, respectively. Fluorescence emission spectra were
performed at room temperature with 670 and 760 nm excitationwave-
lengths for Cy5.5LP and Cy7.5LP loaded nanocarrier, respectively. The
emission spectra were corrected from for the wavelength-dependent
response of the detector. All ﬂuorescence measurements were done
using solutions with absorbance ≤0.1 at the wavelength of excitation.
The relative ﬂuorescence quantum yield was measured using DiD dye
in methanol (QY = 33%) as reference using excitation at 630 nm [47].
2.5. FRET-based stability test
The stability of lipid nanocarriers was estimated using Forster reso-
nance Energy transfer (FRET) between two encapsulated dyes, 1% of
Cy5.5LP (with respect to Labrafac WL®) as energy donor and 1% of
Cy7.5LP as energy acceptor were used. The NCs were diluted 10,000
times from the original formulation and incubated in water and 100%
of fetal bovine serum (FBS). High dilution was needed to avoid satura-
tion of serumby lipids of NCs. The donor in the nanocarrierswas excited
at 670 nm. The semi-quantitative parameter of FRET efﬁciency was cal-
culated according to the following equation E= A/(A+ D) [48], where
A and D are the maximum of ﬂuorescence intensity of the acceptor and
donor, respectively.
2.6. Cytotoxicity studies
In 96-well plates, HeLa cells were seeded at a concentration of
1 × 104 cells per well in 200 μL of the DMEM growth medium and
then incubated overnight at 37 °C in humidiﬁed atmosphere containing
5% CO2. Next, we add the lipid Nanocarriers (1% Cy5.5LP–Cy7.5LP), by
substituting the culturemedium for a similar one containing variable di-
lutions of the Nanocarriers. After incubation for 24 h, the medium was
removed. Then, the wells were ﬁlled with cell culture medium
containing MTT, incubated for 4 h at 37 °C, and the formazan crystals
formed were dissolved by adding 100 μL of DMSO and shaked for
10 min. We measure the absorbance at 570 nm with a microplate
reader (Xenius, Safas). Experiments were carried out in triplicate,
and expressed as a percentage of viable cells compared to the control
group.
2.7. Subcutaneous tumor grafting and administration of FRET nanocarriers
Adult (10 months) immuno-deﬁcient mice (NMRI-Foxn1nu/
Fox1nu, Janvier labs, 1) were anesthetized via gas anesthesia
(isoﬂurane) system prior to tumor cell grafting. Anesthetized mice
were injected subcutaneously (in the ﬂank) with 100 μL of a solution
made of 50% PBS and 50% Matrigel containing 1.106 of D2A1 (murine
mammary carcinoma) cells [49]. Tumors were grown over a period of
20 days before administrating lipid nanocarriers. The mouse studies
were performed according to the Guide for Care and Use of Laboratory
Animals (E67-6-482-21) and the European Directive with approval of
the regional ethical committee (CREMEAS for Comité Régional
d'Ethique en Matière d'Expérimentation Animale de Strasbourg, AL/
73/80/02/13). Mice received food and water ad libitum; they were
checked daily and tumor growth never exceeded 20 days, leading to
low-size tumors with no impact on the animal's health. All efforts
were made to minimize suffering and euthanasia was performed
using CO2. General health status was monitored regularly byindependent observers. Sacriﬁce of the animal was effectuated when
reaching limit ethical endpoints. Before administration of the
nanocarriers solution, mice were anesthetized by intraperitoneal injec-
tion of amixture of ketamine (100mg/kg) and xylazine (10mg/kg). The
nanocarriers were administrated by retro-orbital injection (100 μL) as
previously performed for other purposes [50].
2.8. In vivo whole animal FRET imaging
Whole- and live-animal imaging of the FRET signal in healthy and
tumor-bearingmicewas performed by using a luminograph (NightOwl,
Berthold Technologies). Anesthetized mice (isoﬂurane) were placed re-
peatedly in the luminograph, and positioned either on the ﬂank or the
back. Mice were imaged using a halogen lamp, (75 W, 340–750 nm)
and emission of the twodyeswas collected separately using separateﬁl-
ters sets (630/700 nm for Cy5.5LP, and 630/820 nm for Cy7.5LP). The
experiments with healthy and tumor bearing mice were repeated
three times.
2.9. Calibration of the ratiometric response of NCs to disintegration
To calibrate the ratiometric response of NCs to disintegration in our
in vivo imaging setup, wemodel the disintegration NCs bymixing intact
FRET NCs with NCs containing separately donor and acceptor at low
concentration, with the preservation of the same concentration of
dyes: 100% integrity corresponds to FRET NCs (1% of Cy5.5LP and 1%
of Cy7.5LP) diluted in PBS 1000-fold from the original formulation,
while 0% integrity corresponds to amixture of NCs containing separate-
ly donor (0.1% of Cy5.5LP) and acceptor (0.1% Cy7.5LP), both diluted at
100-fold in PBS. Intermediate mixtures were made, where the level of
integrity (%) is deﬁned as the fraction of Cy5.5LP/Cy7.5LP dyes in the
FRET NCs with respect to the total amount of these dyes. They were
placed into 96-well plate and imaged using the NightOwl setup. The
measurements were done in triplicate. The obtained values of the A/
(A + D) ratio were plotted vs % of integrity and the data were ﬁt with
an exponential function (1):
y ¼ aþ becx ð1Þ
where a=0.14572; b=0.1254; c=0.01748, y is A/(A+D) and x is
FRET pair concentration (wt%).
As anothermodel of the complete disintegration of NCs, solution FRET
NCs diluted 1000-fold in dioxane was placed into 1 mL Eppendorf®
tube and imaged by the NightOwl setup.
2.10. Image analysis of the FRET signal in the living mice
The ratiometric images were built using a homemade plugin (devel-
oped by Romain Vauchelles) under ImageJ that divides the image of the
840 nm channel by that of the 700 nm channel. For each pixel, a
pseudocolor scale is used for coding the ratio, while the intensity is de-
ﬁned by the integral intensity recorded for both channels at the corre-
sponding pixel. Image analysis was performed by using the ImageJ
software [51]. The tail vein, liver and tumor were manually delimitated
and the mean intensity of the delimitated region was determined for
each respective time point and channel for three healthy and three
tumor-bearing mice. For both donor and acceptor channels, the signal
was corrected for the background using the mice before injection (in
the corresponding region of interest). Then the corrected values of A/
(A + D) were converted into the FRET pair concentration using Eq.
(1). The obtained values of FRET pair concentration were then plotted
vs time and ﬁtted using a logistic function (2):
y ¼ a2 þ a1−a2ð Þ
ð1þ xx0
 p ð2Þ
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ters were calculated during the ﬁtting procedure. This ﬁt was further
used to calculate the integrity half-life.
2.11. Statistical analysis
Student's t-test was used to evaluate the statistical signiﬁcance
between two sample groups. The differences between the results were
considered to be signiﬁcant when the p-values were b0.05.
3. Results and discussion
Nanoemulsions were selected as NCs for several reasons. First, they
are very efﬁcient at encapsulating materials. Second, nanoemulsions
can be easily formulated by spontaneous emulsiﬁcation with non-
toxic compounds compatible with the parenteral administration route,
so that they can be intravenously injected at high concentrations into
mice with minimal harm [34,35]. The latter is particularly attractive to
achieve superior contrast for imaging nanocarriers directly in the
blood circulation. Cyanines 5.5 and 7.5 dyes were selected for encapsu-
lation, because they are an excellent FRET couple with ideal spectral
properties for in vivowhole-animal imaging. Indeed, cyanine 5.5 deriv-
atives are among the most commonly used NIR imaging agents with
convenient excitation 650–700 nm and emission in NIR region
(N700 nm). Moreover, cyanine 7.5 absorption spectrum overlaps per-
fectly with the emission spectrum of cyanine 5.5 (Fig. S2), while its
emission in NIR region at 840 nm is perfectly separated from the emis-
sion of cyanine 5.5, making this couple perfectly tailored for ratiometric
FRET imaging. To achieve both strong brightness and highly efﬁcient
FRET inside NCs, cyanines 5.5 and 7.5 should be encapsulated at very
high concentrations up to 1 wt% in oil, as we earlier showed for
other FRET pair [41]. Therefore, their hydrophobic analogues,
dioctadecylcyanines 5.5 (2) and 7.5 (3), were synthesized bearing
long alkyl chains to ensure their high lipophilicity. Nevertheless, their
solubility in labrafac oil (medium chain triglycerides) was only
0.15 and 0.05 wt%, for 2 and 3, respectively. Therefore, we replaced
their inorganic counterion (chloride) with bulky hydrophobic
tetraphenylborate, which, according to our earlier study, improved
drastically the solubility of the cyanine 3 dye DiI [44]. The obtained
new salts, Cy5.5LP and Cy7.5LP (Fig. 1), showed much higher solubility
in labrafac, 7 and 4 wt%, respectively. Then, nano-emulsions (lipid NCs)
were generated by the spontaneous emulsiﬁcation of dye-loaded oil
and non-ionic surfactant (Cremophor® ELP), giving rise to ﬂuorescent
PEGylated droplets sizing around 90–100 nm (Table S1). To generate
FRET NCs, we prepared NCs encapsulating increasing amount of
Cy5.5LP and Cy7.5LP. As expected, the emission spectra recorded afterFig. 2. FRET in the lipid NCs. (A) Fluorescence spectra of dye-loadedNCs as a function ofweight %
fold dilution of NCs inwater. (B) Disintegration of NCs by dioxane: ﬂuorescence spectra of NCs e
Stability of FRET NCs in serum: FRET signal, expressed as A/(A + D) ratio, for different incubat
10,000-fold dilution from original formulation was used. Excitation wavelength was systematiexcitation of the energy donor showed strong dependence on the con-
centration of the FRET pair (Fig. 2A). Thus, at 0.1% of dyes, the emission
spectrum was very close to that of Cy5.5LP alone, while at higher con-
centrations, a long wavelength emission, corresponding to the FRET ac-
ceptor, appeared and became dominant at ≥0.5% of the dyes. It should
be noted that the emission maximum of Cy7.5LP shifted gradually to
the red with increase in the dye content (Fig. 2A). Similar concentra-
tion-dependent red shifts were previously observed for Cy3 dye
in lipid droplets [44]; they could be related to some aggregation of
the dyes, homo-FRET, as well as to small changes in the oil core
properties at higher dye concentrations. Remarkably, the total
(donor + acceptor) ﬂuorescence quantum yield (QY) of NCs encapsu-
lating FRET pair at 1% loading of each dye was 11%. Although this
value was lower than the QY of NCs with 1% of Cy5.5LP alone (27%), it
remained relatively high to ensure high brightness to these NCs, impor-
tant for in vivo imaging. For comparison, QY of NIR dye indocyanine
green measured in phosphate-buffered saline (PBS) is 2.4% [52]. Here,
we achieved much higher QY already for the FRET system. Moreover,
because NCsminimize potential interactions of loaded dyeswith tissues
in vivo, they allow the use of higher dye concentrations, which is essen-
tial for achieving optimal imaging contrast for NIR imaging.
Then, to verify the response of our FRET NCs to their disintegration,
we forced this process by adding excess of water miscible organic sol-
vent dioxane, which should destroy NCs by solubilizing its components.
As a result, a strong emission of Cy5.5LP dye was observed, while the
emission of Cy7.5LP was fully hampered (Fig. 2B). This result conﬁrmed
that integrity of NCs, where Cy5.5LP and Cy7.5LP are in very close prox-
imity within the NCs, can be assessed based on FRET signal. We next
assessed the stability of these FRET NCs by incubating them in serum
(100%), used asmodel of a biological medium in vivo. As a semi-quanti-
tative parameter of FRET efﬁciency, we used the band intensity ratio of
acceptor to the sumof acceptor and donor, A/(A+D), so-called proxim-
ity ratio [48,53]. This ratio showed only a mild decrease over 24 h of in-
cubation in serum (Fig. 2C) and nearly no change in water,
demonstrating the relative stability of our FRET NCs. Therefore, we con-
cluded that these new FRET NCs, owing to good stability and relative
ease in monitoring their integrity, should be perfectly suited for
whole-animal NIR imaging through intravenous injection.
Before testing the integrity of ourNCs in vivo, we evaluated cytotoxic
effects of NCs by performing a cell viability assay in vitro on tumor cells.
In the dilution range between 10,000 and 500, blank and dye-loaded
FRET NCs did not show any signiﬁcant cytotoxicity (Fig. S3). NCs were
however cytotoxic when used at a 200-fold (and below) dilution. Im-
portantly, the presence of both dyes (Cy5.5LP and Cy7.5LP) in the NCs
had no added cytotoxic effect. It should be noted that the dilution factor
that we further used in our mice experiments corresponded to ~1000-of FRET pair (corresponds to % of each dye). The spectrawere recorded for the same1000-
ncapsulating 1% of Cy5.5LP and 1% of Cy7.5LP diluted 1000-fold inwater or in dioxane. (C)
ion times in 100% serum or water at 37 °C. To avoid saturation of serum by lipids of NCs,
cally 670 nm.
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data.
We then performed whole-animal in vivo NIR imaging of anesthe-
tized and immobilized nude mice (Fig. S4) upon parenteral venous ad-
ministration (retro-orbital) of the FRET NCs suspension, diluted to 50-
fold in PBS (the dye concentration in the injected solution was
0.16 mM). We used 630 nm illumination in order to excite Cy5.5LP
dye. Emission was collected at two wavelengths: at 700 nm to observe
emission of the FRET donor Cy5.5LP, and at 820 nm to observe emission
of the FRET acceptor Cy7.5LP (Fig. 3). In order to evaluate directly FRET
changes independently of concentration, we also generated ratio im-
ages where emission of the acceptor was divided by the emission of
the donor (A/D, Fig. 3). Before injection, only low ﬂuorescence was ob-
served for 700 nm channel and negligible signal at 820 nm (Fig. 3A).
Right after injection (15 min), the emission of Cy7.5LP corresponding
to FRET increased signiﬁcantly, while emission intensities collected in
the Cy5.5LP channel remained very close to auto-ﬂuorescence levels ob-
served before injection (Fig. 3B). This strong FRET ﬂuorescence sug-
gested that the integrity of our FRET NCs was well preserved in vivo
15 min after their parenteral injection. Even more importantly, we ob-
tained high imaging contrast in the FRET channel, where blood circula-
tion could be distinguished, notably in the tail and in the back legs
vasculature (see arrows 1 and 2 in Fig. 3B). Strikingly, efﬁcient FRET
(high A/D ratio in red) highlighted strongly vascularized organs,Fig. 3. FRET imaging of healthy nude mice before (A) and after (B) injection of NIR-FRET
lipid NCs (1% of Cy5.5LP and Cy7.5LP each). Left panels present intensity images of the
Cy5.5LP channel (700 nm), middle panels present images of Cy7.5LP channel (820 nm),
while the right panels present ratiometric images (acceptor/donor). The excitation
wavelength was 630 nm. Numbers of arrows show vasculature of tail (1) and back leg
(2) as well as liver (3) and lungs (4).particularly liver. Other organs sitting above the liver, such as the
lungs and potentially thyroid glands, were also resolved with our FRET
NCs. Thus, the use of ratiometric imaging of whole living mice with
our FRET NCs provided remarkably high resolution, where both the
blood circulation and several important organs were easily revealed.
Further time-course imaging experiment revealed that ﬂuorescence
intensities of our NIR dyes and the associated ratio underwent dramatic
evolution. The ﬂuorescence intensity gradually increased in the Cy5.5LP
channel, and became signiﬁcant after 6 h, reachingmaximal values only
after 24 h. On the contrary, overall FRET intensity gradually decreased,
so that after 24 h it was much lower than that at Cy5.5LP channel (Fig.
4). The ratio (A/D) imaging conﬁrmed the continuous decay of the
FRET signal as the initial red pseudo-color changed to green, and
reached the lowest levels (blue) 24 h post-injection (Fig. 4 and S5). Re-
markably, this color switch corresponded to ~30-fold decrease in the A/
D ratio within 24 h, indicating profound changes of FRET in our NCs as
well as high sensitivity and dynamic range of the ratio imaging. This ex-
periment reveals, using FRET imaging, the time-course of disintegration
of our NCs. When the control NCs, containing only Cy5.5LP were
injected, the emission at the donor (Cy5.5LP) channel wasmuch higher
than that at the acceptor one, whatever the post-injection time (Fig. 4
and S7). The obtained ratio images gave very similar blue pseudo-color-
ing all over the mice body for different post-injection times (Fig. S7), in
agreement with total absence of FRET in the control NCs. They matched
well with the images obtained at 24 h post-injection of the FRET NCs,
where the FRET signal was lost (Fig. 4). Interestingly, we obtained
high-quality contrast in the Cy5.5LP channel 15 min after injection of
our control donor dye-loaded NCs, and could easily discern both the
vasculature network as well as highly-vascularized organs such as the
liver. However, in contrast to the ratio imagingwith FRETNCs, fewer de-
tails were observed (i.e. no lungs and less blood vessels). The time-lapse
experiment showed a gradual decay of the ﬂuorescence intensity from
the tail vasculature (tail vein)with complete disappearance of the signal
after 24 h (Fig. 4 and S8).
To provide connection between observed pseudo-color and the in-
tegrity of our NCs, we performed a calibration of our imaging set-up
with diluted solutions of NCs containingmixturesmodelingdifferent in-
tegrity levels. As our dyes did not show signiﬁcant leakage in serum
even within 24 h, we consider that disintegration of NCs observed in
vivo results in the destruction of the droplets themselves. The latter
would lead to thedilution of the liberated dyes in the surrounding tissue
especially in their lipid structures (lipid membranes and droplets), pro-
ducing the loss of FRET. In this case, tomodel fully disintegrated NCs,we
mixed NCs containing separately donor and acceptor dyes at low con-
centration (0.1%). The ﬁnal concentration of each dye in thismodelmix-
ture was identical to that in our FRET NCs, but in this case donor and
acceptors dyes were isolated from each other and diluted in the oil of
NCs. This system should mimic disintegrated NCs, where liberated do-
nors/acceptor dyes are highly diluted in lipid environments of the tis-
sue. We also prepared mixtures of FRET NCs and NCs containing
separated FRET partners, where % of integrity was deﬁned as the frac-
tion of the dyes in the intact FRET NCs with respect to total amount of
dyes in themixture. Decrease in the integrity level produced drastic var-
iation of the two-band emission of NCs with rapid increase in the donor
emission and less pronounced decrease in the acceptor emission (Fig.
5B). These changes were expected as the fraction of non-FRET NCs in-
creased. Then, using our in vivo imaging setup, we observed that a de-
crease in the NCs integrity correlated with a rapid increase in the
donor channel, with only minor decrease in the acceptor one (Fig. 5C),
in line with the spectroscopic data. Ratiometric images of the intact
FRET NCs appeared in red, which reliably matched the blood circulation
of healthy mice at 15 min after injection (Fig. 4). Subsequently, the de-
crease in theNCs integrity level produced gradual change of the pseudo-
color to yellow, green and then to blue, reﬂecting the drop of the A/D
ratio (Fig. 5C). Remarkably, changes in the pseudo-color of our calibrat-
ing solution followed the same trend as those in the ratiometric images
Fig. 4. FRET imaging of healthy nude mice at different times after injection with NIR-FRET lipid NCs (1% of Cy5.5LP and Cy7.5LP each) and control NCs containing only Cy5.5LP dye (1%).
Upper panels present intensity images of the Cy5.5LP channel (700 nm), middle panels present images of Cy7.5LP channel (820 nm), while the lower panels present ratiometric images
(acceptor/donor). The excitation wavelength was 630 nm. Experiment was repeated on three mice, the set of data for the other two mice (15 min post-injection) is reported in the
Supplementary information section (Fig. S6).
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served once the NCswere diluted in dioxane (Fig. 5C), whichwas an ad-
ditional model of NCs disintegration. Based on the calibration results,
the ratio images obtained in living mice could directly be correlated to
NCs integrity in vivo. To realize quantitative analysis of the changes in
theNCs integrity, weﬁrst corrected the data from the background signal
in liver and tail vein for both 700 and 820 nm channels, and used them
to obtain the A/(A+ D) ratio, which is used here as a semi-quantitative
measure of the overall FRET efﬁciency in our samples. This ratio
remained stable for 2–3 h post-injection in the tail vein (Fig. 6B), indi-
cating remarkable stability of NCs in the blood circulation. In sharp con-
trast, this ratio showed signiﬁcant drop in the liver, indicating
signiﬁcant loss of FRET and thus NCs integrity on the time scale of 2–
3 h. Althoughwe cannot provide absolute values of FRET efﬁciency sim-
ply based on the A/(A + D) ratio [48,53,54], we could directly correlate
this ratio with the integrity level of NCs (Fig. 5D) using calibration im-
ages in Fig. 5C, recorded by the same imaging setupwith identical emis-
sion ﬁlters. The obtained plot of A/(A+D) ratio vs integrity level of NCs
was ﬁtted using a non-linear equation and then used as our calibration
curve. Consequently, this allowed us to estimate integrity of our NCs
over time for liver and tail vein, directly in living mice (Fig. 6C). This
analysis revealed dramatic difference in the stability of NCs in blood cir-
culation and liver. At 6 h of post-administration, the integrity of NCs in
the liver decreased to 66 ± 2%, whereas in blood circulation NCs
remained practically intact with integrity level reaching 93 ± 2% (Fig.
6C) (p b 0.0003, n = 3). The integrity half-life of NCs was 8.2 ± 0.4 h
in the liver of healthy mice. Unfortunately, this parameter could not
be assessed for the blood circulation since NCs were cleared from the
blood on the shorter time scale. Indeed, our experiments with NCs con-
taining only donor dye (Cy5.5LP) (Fig. S7) conﬁrmed that the circula-
tion half-time was 3 ± 1 h (Fig. S8). Therefore, after 6 h, most of NCs
were cleared from the blood circulation, so the detected signal in the
tail region was produced mainly by surrounding tissues. Thus, the
lipid NCs remain stable until their clearance from the blood. On theother hand, our data suggest that liver can disintegrate lipid NCs on
the time scale of hours.
Next, because NCs bear great potential in tumor targeting, we ad-
ministrated our FRET NCs to tumor-bearing animals, where murine
tumor cells (D2A1) were subcutaneously xenografted in the ﬂank of
nudemice 20 days before NCs injection (see photo of one tumor bearing
mice in Fig. S4). Thus, assuming that EPRwould lead to accumulation of
NCs in tumors, the basic question we asked was whether the NCs enter
tumor in their intact or disintegrated form. Upon administration of NCs,
we observed a signiﬁcant targeting of the microenvironment of the
tumor by our NCs, which led to ﬂuorescence around tumor in the
FRET channel and almost negligible ﬂuorescence in the Cy5.5LP channel
(Fig. 7A and Fig. S9). This ﬂuorescence signal corresponded to high A/D
ratio (observed in red), indicating efﬁcient FRET, similar to that in the
tail vessel. Thus, the ﬂuorescence observed in the peri-tumoral region
can be assigned to the tumor-associated vasculature, which contains
high concentration of intact FRET NCs. Already at 1 h post-injection,
the tumor region displayed very strong FRET signal, even though signal
collected in the Cy5.5LP channel remained very low (Fig. 7A). In this
case, the absolute intensity of the donor channel was only 5.7± 1.3 (ar-
bitrary units, a. u.), whereas for control NCs with only donor Cy5.5LP,
the intensity in the tumor region at 1 h injection was 26 ± 2 (a. u.).
This much lower intensity of the donor channel suggested the efﬁcient
FRET-based quenching of the donor inside the FRET NCs accumulated
in the tumor. Ratio image at 1 h showed mainly yellow-red color in
the tumor region, which indicated that after accumulation in the
tumor the FRET remained very high despite a small decrease. These ob-
servations suggested that (i) the lipid NCs underwent a speciﬁc, rapid
and efﬁcient accumulation into the xenografted tumor, through the
tumor-associated vasculature, and (ii) they remain, to a large extent, in-
tact for at least 1 h within tumor region. Intensity of the FRET signal in
tumor reached maximum values 2 h post-injection and then remained
stable over the time-course of the experiment. In contrast, the ﬂuores-
cence intensity in the donor channel increased slowly over the ﬁrst
Fig. 5. Calibration of ratiometric in vivo images usingmixtures of intact FRET NCswith NCs containing separately donor and acceptor at low concentration. The mixing is done to preserve
the same concentration of dyes: 100% integrity corresponds to FRET NCs (1% of Cy5.5LP and 1% of Cy7.5LP) diluted in PBS 1000-fold from the original formulation, while 0% integrity
corresponds to a mixture of NCs containing separately donor (0.1% of Cy5.5LP) and acceptor (0.1% Cy7.5LP), both diluted at 100-fold in PBS. The latter mixture models the
disintegrated NCs, where donor and acceptor separate and get diluted in the tissue (A). (B) Fluorescence spectra of the obtained solutions. (C) Fluorescence images of these mixtures
acquired with the in vivo imaging set-up: donor (Cy5.5LP) channel (upper panels), acceptor (Cy7.5LP) FRET channel (middle panels), and the acceptor/donor ratio images (lower
panels). NCs containing only donor dye (Cy5.5LP) and FRET NCs diluted 1000-fold in dioxane (second model of the complete disintegration) are also shown. (D) Calibration curve of
A/(A + D) ratio vs the level of integrity of NCs obtained based on data in (C) panel. The error bars represent the standard error of the mean (n= 3).
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ratiometric imaging showed that relative intensity of the FRET acceptor
decreased continuously with time, reaching the lowest values after 24 h
of incubation. Experiments with control NCs containing only donor dye
Cy5.5LP conﬁrmed rapid accumulation of NCs into the tumor region al-
ready at 1 h post-injection (Fig. 7A). The acceptor channel remained
dim in the tumor region, in line with expected absence of FRET. The in-
tensity in the donor channel continued to gradually increase over time,
reaching saturation after 24 h, whereas in the acceptor channel the in-
tensity remained poor (Fig. S11). Imaging of mice organs (Fig. S12) dis-
sected from animals at 24 h post-administration revealed that
ﬂuorescence of tumor was slightly brighter than that of liver (by 30%,
p = 0.02, n = 4). By contrast, ﬂuorescence of other studied organs
(spleen, lungs, heart and kidneys) was many-fold lower (p ≤ 0.0002,
n = 4), suggesting that both tumors and liver are the main targets for
accumulation of our NCs, in line with the whole animal in vivo imaging
data.
After accounting for the background ﬂuorescence, we quantiﬁed the
FRET proximity ratio in tumor-bearingmice by analyzing the A/(A+D)
ratio (Fig. 7B) and then converted it to the NCs integrity level for differ-
ent post-administration times (Fig. 7C). Importantly, after 2 h,when the
signal of NCs from the tumor region was already very strong (Fig. 7A),
the integrity of NCs was still at 77 ± 1% (Fig. 7C), indicating that theyFig. 6.Quantitative analysis of NCs integrity in livingmice. (A) Ratio image of healthymice show
(B) and integrity (C) of NCs in different regions of healthymice as a function of post-administra
too low. Three mice were analyzed, the error bars represent the standard error of the mean (ncould enter the tumor with minimal loss of integrity. Nevertheless, the
loss of integrity was faster than in the blood circulation. Indeed, in tail
vein after 6 h NCs integrity was at 71 ± 3%, whereas for tumor it
dropped already to 40 ± 4% (Fig. 7C) (p b 0.003, n = 3). The integrity
half-life for our NCs in tumor was 4.4 ± 0.3 h, which was even faster
than in the liver of healthymice (8.2 ± 0.4 h, p b 0.001, n= 3).We pro-
vide the ﬁrst evidence for the kinetics of disintegration of lipid NCs in
tumor bearing mice in vivo and show that the lipid NCs preserve their
content in the blood circulation, then they can enter tumors with mini-
mal loss of integrity and ﬁnally after accumulation in the tumors they
disintegrate on the time scale of hours. One should also note that disin-
tegration of NCs inside blood circulation of tumor bearingmicewas con-
siderably faster than in healthy mice, which can be seen from the
integrity levels at 6 h of post-administration (71 ± 3% vs 93 ± 2%,
p b 0.003, n = 3). On the other hand, the clearance from blood circula-
tion, measured using control NCs bearing only Cy5.5LP (Fig. S11) in
tumor-bearing mice was similar to that in healthy mice (Fig. S8).
In conclusion, we propose here an original approach to obtain near-
infrared lipid nanocarriers with efﬁcient FRET and excellent brightness.
It is based on hydrophobic counterions that increase many-fold the sol-
ubility of cyanines dyes in oil and thereby enable their high loading in-
side NCs, required for FRET. We provide here clear demonstration that
these new NCs allow reliable imaging and monitoring NCs' integrity ining the regions of interest: liver (1) and tail vein (2). (B, C) Analysis of the A/(A+D) ratio
tion time. Ratio analysis in the tail veinwas done until 6 h, because after that the signal was
= 3).
Fig. 7. (A) FRET imaging of tumor-bearing nudemice at different times after injectedwith NIR-FRET lipid NCs (1% of Cy5.5LP and Cy7.5LP each) or control NCs with donor dye only (1% of
Cy5.5LP dye). Upper panels present intensity images of the Cy5.5LP channel (700 nm), middle panels present images of Cy7.5LP channel (820 nm), while the lower panels present
ratiometric images (acceptor/donor). The excitation wavelength was 630 nm. Experiment was repeated on three mice, the set of data for the other two mice is reported in the
Supplementary information section (Fig. S10). (B, C) Analysis of the A/(A + D) ratio (B) and integrity (C) of NCs in different regions of tumor-bearing mice as a function of post-
administration time. Three mice were analyzed, the error bars represent the standard error of the mean (n = 3). (D) Fluorescence intensity of organs dissected from animals at 24 h
post-administration with NCs containing 1% of Cy5.5LP dye. The error bars corresponds to standard error of the mean (n = 4). Images of organs are presented in Fig. S12.
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higher resolution compared to existing FRET systems for in vivo imaging
[9,24,25]. Importantly, wewere able to accurately resolve the follow-up
of NCs integrity directly in the blood circulation of living mice, which
was possible before only by using dedicated intravital microscopy [9,
27]. The high-quality of the obtained images is probably due to relative-
ly high ﬂuorescence quantum yield, dye-loading and injection dose, as
well as optimal NIR spectral excitation and emission windows of our
FRET NCs. Moreover, by dividing two emission channels, we generated
high quality ratiometric images capable of resolving some features of
the vascular system and tissues that are usually not assessable by live
whole-animal ﬂuorescence imaging. The intensity ratio is the absolute
parameter,which is almost independent on the concentration of the im-
aging agent and excitation light intensity [31,32,55,56]. Therefore, the
ratio signal provides quantitative information about the changes in the
emission spectra of the probe in the imaged system. In our case, due
to calibration of the spectral response of the FRET NCs directly under
the in vivo imaging setup, we achieved a reliable read-out of the integ-
rity of our NCs by ratiometric analysis, which would not be possible
using absolute intensity measurements. It should be noted that in addi-
tion to calibration of the imaging system, this method requires subtrac-
tion of the background, which is relatively high in small animal
ﬂuorescence imaging. One important point that is difﬁcult to take into
account is the difference in the penetration depth for 700- and 820-
nm light [30], which may affect the precision of the quantitative
analysis.The describedmethodology enabled, for theﬁrst time, to quantify by
in vivo ﬂuorescence imaging the integrity of NCs in different regions of
healthy and tumor-bearing mice. It revealed that injected NCs remain
nearly intact after 6 h in the blood circulation of healthy mice, whereas
their integrity signiﬁcantly dropped to 66 ± 2% in the liver of healthy
mice, and up to 40± 4% in tumors. Nevertheless, lipid NCs appeared re-
markably stable as they could enter tumors rapidly withminimal loss of
integrity, showing for instance 77± 1% of the integrity at 2 h of post-in-
jection. Thus, NCs can preserve their content in the blood circulation,
enter tumors in nearly intact form and then release this content on
the time scale of hours. This data shows the strong potential of NCs as
efﬁcient carriers of drugs and contrast agents. The remarkable stability
of lipid NCs is an important ﬁnding of this work. Commonly,
nanoemulsions are considered as liquid systems that should not be sta-
ble enough in vivo and require, for instance, specially designed surface of
lipids with long PEG chains [25,36]. However, in the present work, we
showed for the ﬁrst time that nanoemulsion droplets built only from
oil (medium chain triglycerides) and a surfactant (Cremophor® ELP)
exhibited no signs of disintegration in blood circulation for hours. This
result contrasts stronglywith thepoor capacity of theseNCs to keepme-
dium polar molecules like Nile Red, which is rapidly released in biolog-
ical media [41,57].
Our NCs showed remarkably efﬁcient accumulation in tumors,
which can be clearly assigned to the EPR effect originating from the
leaky nature of the tumor vesicles [15,58]. The efﬁciency of the passive
EPR tumor accumulation is generally proportional to the circulation
66 R. Bouchaala et al. / Journal of Controlled Release 236 (2016) 57–67time of the agent in the bloodstream. In this respect, our NCs present
dense PEG shell which is known to prolong the circulation time of nano-
particles [59].
Finally, the key ﬁnding that has never been shown for lipid NCs is
their capacity to accumulate in tumors in nearly intact form. This prop-
erty is known for polymer nanoparticles, which are established drug de-
livery vehicles into tumors [60,61], and inorganic nanoparticles, such as
quantum dots covered with robust organic shell [9,62]. The capacity of
our nano-emulsion droplets to preserve their integrity after accumula-
tion in tumors is particularly remarkable given the liquid nature of
their core. This result shows the strong potential of these lipid NCs as
nanoscale platform for in vivo imaging, drug delivery and image guided
surgery.
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